iX Biopharma (SGX:42C) Total Assets : S$13.08 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Total Assets?

iX Biopharma's Total Assets for the quarter that ended in Dec. 2024 was S$13.08 Mil.

During the past 12 months, iX Biopharma's average Total Assets Growth Rate was -9.80% per year. During the past 3 years, the average Total Assets Growth Rate was 0.50% per year. During the past 5 years, the average Total Assets Growth Rate was 7.40% per year. During the past 10 years, the average Total Assets Growth Rate was 6.90% per year.

During the past 11 years, iX Biopharma's highest 3-Year average Total Assets Growth Rate was 25.00%. The lowest was -9.90%. And the median was 6.70%.

Total Assets is connected with ROA %. iX Biopharma's annualized ROA % for the quarter that ended in Dec. 2024 was -90.23%. Total Assets is also linked to Revenue through Asset Turnover. iX Biopharma's Asset Turnover for the quarter that ended in Dec. 2024 was 0.27.

iX Biopharma Total Assets Historical Data

The historical data trend for iX Biopharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Total Assets Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Assets

Get a 7-Day Free Trial

16.98

18.86

28.52

24.93

14.62

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Assets	Get a 7-Day Free Trial															25.82	24.93	18.31	14.62	13.08

iX Biopharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

iX Biopharma's Total Assets for the fiscal year that ended in Jun. 2024 is calculated as

Total Assets	=	Total Equity (A: Jun. 2024 )	+	Total Liabilities (A: Jun. 2024 )
	=	4.34	+	10.284
	=	14.62

iX Biopharma's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	3.514	+	9.57
	=	13.08

iX Biopharma (SGX:42C) Total Assets Explanation

Total Assets is connected with ROA %.

iX Biopharma's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-12.5	/	( (14.624	+	13.084)	/ 2 )
	=	-12.5	/	13.854
	=	-90.23 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

iX Biopharma's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	3.713	/	( (14.624	+	13.084)	/ 2 )
=	3.713	/	13.854
=	0.27

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

iX Biopharma Total Assets Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines